Companies/Delota Corp.

Company profile

Delota Corp.

OTC: SYDRF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Concord, ONReports USD

#502 of 1,394 Healthcare companies by revenue62nd-percentile growth

EA Score

——

FH —DQ —GM —SS 40

v0.1 · 5/100 weight · pillars only

↑ return on equity, return on assets · ↓ growth stability, listing tenure

Methodology →

Revenue TTM

$26.8M

Rev growth YoY (TTM)

+5.2%

Net income (FY)

$407.6k

Employees

140

Market cap

$2.9M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$29.2M40.2M CAD2025

Net income$407.6k561.8k CAD2025

Operating income$349.7k482.0k CAD2025

Total assets$10.2M14.8M CAD2025

Liabilities$9.4M13.6M CAD2025

Equity$819.1k1.2M CAD2025

Revenue trend

FY2018 – FY2025 · USD

$465.4k

FY18

$567.5k

FY19

$431.6k

FY20

$953.2k

FY21

$14.1M

FY22

$19.8M

FY23

$25.2M

FY24

$29.2M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Delota Corp. booked $29.2M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a 1.4% net margin.

Peers · Healthcare

CNS Pharmaceuticals, Inc.——Medican Enterprises, Inc.——Veltex Corporation49D Dogwood Therapeutics, Inc.——

Key facts

CEORobert Cameron-Takehiko Wickham

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersConcord, ON

ExchangeOTC: SYDRF

Employees140

IPO date2021-10-27

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.